{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T10:31:04Z","timestamp":1785493864902,"version":"3.56.0"},"reference-count":39,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2023,6,29]],"date-time":"2023-06-29T00:00:00Z","timestamp":1687996800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"JSPS KAKENHI Grant-in-Aid for Scientific Research (C)","doi-asserted-by":"publisher","award":["21K06703"],"award-info":[{"award-number":["21K06703"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"JSPS KAKENHI Grant-in-Aid for Scientific Research (C)","doi-asserted-by":"publisher","award":["226005"],"award-info":[{"award-number":["226005"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005610","name":"Fukuoka University","doi-asserted-by":"publisher","award":["21K06703"],"award-info":[{"award-number":["21K06703"]}],"id":[{"id":"10.13039\/501100005610","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005610","name":"Fukuoka University","doi-asserted-by":"publisher","award":["226005"],"award-info":[{"award-number":["226005"]}],"id":[{"id":"10.13039\/501100005610","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Bortezomib (BTZ), a chemotherapeutic drug used to treat multiple myeloma, induces life-threatening side effects, including severe pulmonary toxicity. However, the mechanisms underlying these effects remain unclear. The objectives of this study were to (1) investigate whether BTZ influences vascular permeability and (2) clarify the effect of BTZ on the expression of molecules associated with cell\u2013cell junctions using human pulmonary microvascular endothelial cells in vitro. Clinically relevant concentrations of BTZ induced limited cytotoxicity and increased the permeability of human pulmonary microvascular endothelial cell monolayers. BTZ decreased the protein expression of claudin-5, occludin, and VE-cadherin but not that of ZO-1 and \u03b2-catenin. Additionally, BTZ decreased the mRNA expression of claudin-5, occludin, ZO-1, VE-cadherin, and \u03b2-catenin. Our results suggest that BTZ increases the vascular permeability of the pulmonary microvascular endothelium by downregulating cell\u2013cell junction molecules, particularly claudin-5, occludin, and VE-cadherin.<\/jats:p>","DOI":"10.3390\/ijms241310842","type":"journal-article","created":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T00:43:30Z","timestamp":1688085810000},"page":"10842","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Bortezomib Increased Vascular Permeability by Decreasing Cell\u2013Cell Junction Molecules in Human Pulmonary Microvascular Endothelial Cells"],"prefix":"10.3390","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5301-1481","authenticated-orcid":false,"given":"Taichi","family":"Matsumoto","sequence":"first","affiliation":[{"name":"Basic Medical Research Unit, St. Mary\u2019s Research Center, 422, Tsubuku-honmachi, Kurume 830-8543, Fukuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7464-5819","authenticated-orcid":false,"given":"Junichi","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Care and Health Sciences, Faculty of Pharmaceutical Sciences, Fukuoka University, 8-19-1, Nanakuma, Jonan-ku, Fukuoka 814-0180, Fukuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuka","family":"Matsushita","sequence":"additional","affiliation":[{"name":"Department of Drug Informatics and Translational Research, Faculty of Pharmaceutical Sciences, Fukuoka University, 8-19-1, Nanakuma, Jonan-ku, Fukuoka 814-0180, Fukuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moeno","family":"Arimura","sequence":"additional","affiliation":[{"name":"Department of Drug Informatics and Translational Research, Faculty of Pharmaceutical Sciences, Fukuoka University, 8-19-1, Nanakuma, Jonan-ku, Fukuoka 814-0180, Fukuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Aono","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Care and Health Sciences, Faculty of Pharmaceutical Sciences, Fukuoka University, 8-19-1, Nanakuma, Jonan-ku, Fukuoka 814-0180, Fukuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikiko","family":"Aoki","sequence":"additional","affiliation":[{"name":"Department of Pathology, Faculty of Medicine, Fukuoka University, 7-45-1, Nanakuma, Jonan-ku, Fukuoka 814-0180, Fukuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Terada","sequence":"additional","affiliation":[{"name":"Division of Pharmacotherapeutics, Faculty of Pharmaceutical Sciences, Himeji Dokkyo University, 7-2-1, Kamiohno, Himeji 670-8524, Hyogo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayoshi","family":"Mori","sequence":"additional","affiliation":[{"name":"Department of Pharmacotherapeutics, Faculty of Pharmaceutical Sciences, Fukuoka University, 8-19-1, Nanakuma, Jonan-ku, Fukuoka 814-0180, Fukuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Haramaki","sequence":"additional","affiliation":[{"name":"Psychology Program, Graduate School of Humanities and Social Sciences, Hiroshima University, Kagamiyama, 1-1-1, Kagamiyama, Higashi-Hiroshima City 739-8512, Hiroshima, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Imatoh","sequence":"additional","affiliation":[{"name":"Department of Drug Informatics and Translational Research, Faculty of Pharmaceutical Sciences, Fukuoka University, 8-19-1, Nanakuma, Jonan-ku, Fukuoka 814-0180, Fukuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5640-3973","authenticated-orcid":false,"given":"Atsushi","family":"Yamauchi","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Care and Health Sciences, Faculty of Pharmaceutical Sciences, Fukuoka University, 8-19-1, Nanakuma, Jonan-ku, Fukuoka 814-0180, Fukuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Migita","sequence":"additional","affiliation":[{"name":"Department of Drug Informatics and Translational Research, Faculty of Pharmaceutical Sciences, Fukuoka University, 8-19-1, Nanakuma, Jonan-ku, Fukuoka 814-0180, Fukuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,6,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1634\/theoncologist.8-6-508","article-title":"Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy","volume":"8","author":"Kane","year":"2003","journal-title":"Oncologist"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1056\/NEJM199704103361506","article-title":"Nuclear factor-kappaB: A pivotal transcription factor in chronic inflammatory diseases","volume":"336","author":"Barnes","year":"1997","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S0093-7754(01)90034-X","article-title":"Proteasome inhibition in cancer: Development of PS-341","volume":"28","author":"Adams","year":"2001","journal-title":"Semin. Oncol."},{"key":"ref_4","first-page":"3071","article-title":"The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells","volume":"61","author":"Hideshima","year":"2001","journal-title":"Cancer Res."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Pancheri, E., Guglielmi, V., Wilczynski, G.M., Malatesta, M., Tonin, P., Tomelleri, G., Nowis, D., and Vattemi, G. (2020). Non-Hematologic Toxicity of Bortezomib in Multiple Myeloma: The Neuromuscular and Cardiovascular Adverse Effects. Cancers, 12.","DOI":"10.3390\/cancers12092540"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1182\/blood-2006-03-011494","article-title":"Severe pulmonary complication after bortezomib treatment for multiple myeloma","volume":"108","author":"Boyer","year":"2006","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3492","DOI":"10.1182\/blood-2005-11-4541","article-title":"Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myeloma","volume":"107","author":"Miyakoshi","year":"2006","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1080\/10428190600988010","article-title":"Development of fatal bortezomib induced acute lung injury despite concurrent therapy with high-dose dexamethasone","volume":"48","author":"Chew","year":"2007","journal-title":"Leuk. Lymphoma"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2913124","DOI":"10.1155\/2018\/2913124","article-title":"Bortezomib-Induced Pulmonary Toxicity: A Case Report and Review of Literature","volume":"2018","author":"Kharel","year":"2018","journal-title":"Case Rep. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1002\/ajh.20891","article-title":"Pulmonary fibrosis in a myeloma patient on bortezomib treatment. A new severe adverse effect of a new drug","volume":"82","author":"Duek","year":"2007","journal-title":"Am. J. Hematol."},{"key":"ref_11","first-page":"1859","article-title":"Lung injury associated with bortezomib therapy in Japan","volume":"52","author":"Mukai","year":"2011","journal-title":"Rinsho Ketsueki"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.exphem.2021.02.009","article-title":"Bortezomib enhances G-CSF-induced hematopoietic stem cell mobilization by decreasing CXCL12 levels and increasing vascular permeability","volume":"97","author":"Matsumoto","year":"2021","journal-title":"Exp. Hematol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1200\/JCO.2004.02.106","article-title":"Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer","volume":"22","author":"Papandreou","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.3324\/haematol.13285","article-title":"Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma","volume":"93","author":"Moreau","year":"2008","journal-title":"Haematologica"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1007\/s00280-011-1637-5","article-title":"Dose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: A National Cancer Institute Organ Dysfunction Working Group Study","volume":"68","author":"Leal","year":"2011","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Takata, F., Dohgu, S., Yamauchi, A., Matsumoto, J., Machida, T., Fujishita, K., Shibata, K., Shinozaki, Y., Sato, K., and Kataoka, Y. (2013). In vitro blood-brain barrier models using brain capillary endothelial cells isolated from neonatal and adult rats retain age-related barrier properties. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0055166"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1016\/j.clinthera.2009.11.012","article-title":"Effect of the CYP3A inhibitor ketoconazole on the pharmacokinetics and pharmacodynamics of bortezomib in patients with advanced solid tumors: A prospective, multicenter, open-label, randomized, two-way crossover drug-drug interaction study","volume":"31","author":"Venkatakrishnan","year":"2009","journal-title":"Clin. Ther."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"L593","DOI":"10.1152\/ajplung.00386.2006","article-title":"Cell-cell adhesion in lung endothelium","volume":"292","author":"Shasby","year":"2007","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1111\/j.1349-7006.2010.01544.x","article-title":"Bortezomib potentially inhibits cellular growth of vascular endothelial cells through suppression of G2\/M transition","volume":"101","author":"Tamura","year":"2010","journal-title":"Cancer Sci."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1124\/dmd.105.005710","article-title":"Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4, to the hepatic metabolism of the proteasome inhibitor bortezomib","volume":"33","author":"Uttamsingh","year":"2005","journal-title":"Drug Metab. Dispos."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Fatunde, O.A., and Brown, S.A. (2020). The Role of CYP450 Drug Metabolism in Precision Cardio-Oncology. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21020604"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nrd.2015.21","article-title":"From blood-brain barrier to blood-brain interface: New opportunities for CNS drug delivery","volume":"15","author":"Banks","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/nature25739","article-title":"A molecular atlas of cell types and zonation in the brain vasculature","volume":"554","author":"Vanlandewijck","year":"2018","journal-title":"Nature"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41598-018-36731-3","article-title":"Claudin-3-deficient C57BL\/6J mice display intact brain barriers","volume":"9","author":"Coisne","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jconrel.2021.06.009","article-title":"Safety and efficacy of an anti-claudin-5 monoclonal antibody to increase blood-brain barrier permeability for drug delivery to the brain in a non-human primate","volume":"336","author":"Tachibana","year":"2021","journal-title":"J. Control. Release"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"8383","DOI":"10.1038\/s41598-018-26560-9","article-title":"Engineered membrane protein antigens successfully induce antibodies against extracellular regions of claudin-5","volume":"8","author":"Hashimoto","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Clark, P.R., Kim, R.K., Pober, J.S., and Kluger, M.S. (2015). Tumor necrosis factor disrupts claudin-5 endothelial tight junction barriers in two distinct NF-kappaB-dependent phases. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0120075"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"113554","DOI":"10.1016\/j.expneurol.2020.113554","article-title":"Escin ameliorates the impairments of neurological function and blood brain barrier by inhibiting systemic inflammation in intracerebral hemorrhagic mice","volume":"337","author":"Ding","year":"2021","journal-title":"Exp. Neurol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"106610","DOI":"10.1016\/j.intimp.2020.106610","article-title":"PIK3R3 regulates ZO-1 expression through the NF-kB pathway in inflammatory bowel disease","volume":"85","author":"Ibrahim","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1007\/s00018-019-03260-9","article-title":"Compensatory increase of VE-cadherin expression through ETS1 regulates endothelial barrier function in response to TNFalpha","volume":"77","author":"Barroso","year":"2020","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"3797","DOI":"10.1093\/emboj\/16.13.3797","article-title":"beta-catenin is a target for the ubiquitin-proteasome pathway","volume":"16","author":"Aberle","year":"1997","journal-title":"EMBO J."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"4319","DOI":"10.1182\/blood-2008-08-174300","article-title":"Bortezomib induces osteoblast differentiation via Wnt-independent activation of beta-catenin\/TCF signaling","volume":"113","author":"Qiang","year":"2009","journal-title":"Blood"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"C977","DOI":"10.1152\/ajpcell.90607.2007","article-title":"VE-cadherin and beta-catenin binding dynamics during histamine-induced endothelial hyperpermeability","volume":"294","author":"Guo","year":"2008","journal-title":"Am. J. Physiol. Cell. Physiol."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Prakoso, A.T., Basri, H., Adanta, D., Yani, I., Ammarullah, M.I., Akbar, I., Ghazali, F.A., Syahrom, A., and Kamarul, T. (2023). The Effect of Tortuosity on Permeability of Porous Scaffold. Biomedicines, 11.","DOI":"10.3390\/biomedicines11020427"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Ammarullah, M.I., Afif, I.Y., Maula, M.I., Winarni, T.I., Tauviqirrahman, M., Akbar, I., Basri, H., van der Heide, E., and Jamari, J. (2021). Tresca Stress Simulation of Metal-on-Metal Total Hip Arthroplasty during Normal Walking Activity. Materials, 14.","DOI":"10.3390\/ma14247554"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Ammarullah, M.I., Hartono, R., Supriyono, T., Santoso, G., Sugiharto, S., and Permana, M.S. (2023). Polycrystalline Diamond as a Potential Material for the Hard-on-Hard Bearing of Total Hip Prosthesis: Von Mises Stress Analysis. Biomedicines, 11.","DOI":"10.3390\/biomedicines11030951"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Ammarullah, M.I., Santoso, G., Sugiharto, S., Supriyono, T., Wibowo, D.B., Kurdi, O., Tauviqirrahman, M., and Jamari, J. (2022). Minimizing Risk of Failure from Ceramic-on-Ceramic Total Hip Prosthesis by Selecting Ceramic Materials Based on Tresca Stress. Sustainability, 14.","DOI":"10.3390\/su142013413"},{"key":"ref_38","first-page":"31","article-title":"Tresca stress study of CoCrMo-on-CoCrMo bearings based on body mass index using 2D computational model","volume":"33","author":"Ammarullah","year":"2022","journal-title":"J. Tribol."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Salaha, Z.F.M., Ammarullah, M.I., Abdullah, N., Aziz, A.U.A., Gan, H.S., Abdullah, A.H., Abdul Kadir, M.R., and Ramlee, M.H. (2023). Biomechanical Effects of the Porous Structure of Gyroid and Voronoi Hip Implants: A Finite Element Analysis Using an Experimentally Validated Model. Materials, 16.","DOI":"10.3390\/ma16093298"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/13\/10842\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:03:28Z","timestamp":1760126608000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/13\/10842"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,29]]},"references-count":39,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2023,7]]}},"alternative-id":["ijms241310842"],"URL":"https:\/\/doi.org\/10.3390\/ijms241310842","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,29]]}}}